乙型肝炎核心抗体水平与HBeAg血清阴性患者HBV DNA及HBsAg清除相关
该回顾性研究基于台湾社区队列2500例HBeAg血清阴性者,发现抗-HBc<3 log IU/mL者HBV DNA不可测及HBsAg清除比例更高,联合HBsAg、HBV DNA与抗-HBc的模型预测10年内HBsAg清除的AUROC为82%。
要点
- 抗-HBc<3 log IU/mL者HBV DNA不可测比例58%、HBsAg清除比例53%,高于抗-HBc较高者的29.6%和19.8%(P<.001)。
- HBsAg<102 IU/mL且抗-HBc<3 log IU/mL者HBV DNA不可测的校正率比为16.45(95%CI 11.15-24.28)。
- 联合抗-HBc的模型预测10年内HBsAg清除的AUROC为82%,高于仅含HBV DNA和HBsAg的模型(P<.0001)。
核心结论
- 在台湾慢性HBV感染大规模队列的回顾性分析中,抗-HBc<3 log IU/mL与10年内HBV DNA不可测及HBsAg清除相关,同时HBsAg<102 IU/mL者几率更大。
- 联合HBsAg、HBV DNA和抗-HBc水平可识别能实现HBsAg清除的HBeAg血清阴性患者,AUROC为82%。
研究设计与样本
- 回顾性分析台湾社区队列中1991年至1992年招募的30-65岁HBsAg血清阳性、抗-HCV阴性且无肝硬化和/或肝癌的个体,每6-12个月随访至2004年6月30日。
- 检测2500名HBeAg血清阴性参与者的抗-HBc水平,以首次且后续持续阴性判定自发HBV DNA不可测或HBsAg清除的日期。
- 采用Cox比例风险回归估计抗-HBc水平与HBV DNA不可测或HBsAg清除的关联,并用AUROC分析评估时间对抗-HBc与HBsAg清除关联的影响。
主要发现
- 随访12年后,抗-HBc<3 log IU/mL者HBV DNA不可测比例为58%、HBsAg清除比例为53%,高于抗-HBc较高者的29.6%和19.8%(P<.001)。
- HBsAg<102 IU/mL且抗-HBc<3 log IU/mL者相比HBsAg和抗-HBc均较高者,HBV DNA不可测的校正率比为16.45(95%CI 11.15-24.28),HBsAg清除的校正率比为17.95(95%CI 12.49-25.81)。
- 包含抗-HBc水平的模型识别10年内HBsAg清除的AUROC为82%,显著高于仅含HBV DNA和HBsAg水平的模型(P<.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Although a low level of hepatitis B surface antigen (HBsAg) is a marker of hepatitis B virus (HBV) seroclearance, additional biomarkers are needed for more accurate prediction. We investigated whether quantification of antibody against HBV core protein (anti-HBc) can identify patients with undetectable levels of HBV DNA and HBsAg seroclearance among those who were HBV e antigen (HBeAg)-seronegative. METHODS: We performed a retrospective analysis of data from a community-based cohort of individuals (30-65 years old) in Taiwan who were HBsAg seropositive, anti-HCV negative, and free of cirrhosis and/or liver cancer, recruited from 1991 through 1992, and evaluated every 6-12 months until June 30, 2004. We measured levels of anti-HBc in blood samples from 2500 participants who were seronegative for HBeAg. The first date at which a sample tested negative for HBV DNA or HBsAg, and remained negative in subsequent tests, was designated as the date of spontaneous HBV DNA undetectability or HBsAg seroclearance. We calculated cumulative incidences of HBV DNA undetectability and HBsAg seroclearance; associations between level of anti-HBc and undetectability of HBV DNA or HBsAg seroclearance were estimated by Cox proportional hazard regression. The effects of time on the associations between level of anti-HBc and HBsAg seroclearance was assessed by the area under the receiver operating characteristic curve (AUROC) analysis. RESULTS: After a 12-year follow-up period, higher proportions of subjects with levels of anti-HBc <3 log IU/mL had undetectable levels of HBV DNA (58%) and HBsAg seroclearance (53%) than subjects with higher levels of anti-HBc (29.6% and 19.8%, respectively) (P < .001). For subjects with levels of HBsAg <102 IU/mL and anti-HBc <3 log IU/mL, the adjusted rate ratio of HBV DNA undetectability was 16.45 (95% CI, 11.15-24.28) and of HBsAg seroclearance was 17.95 (95% CI, 12.49-25.81), compared to subjects with higher levels of HBsAg and anti-HBc. A model that included level of anti-HBc as a parameter identified subjects with HBsAg seroclearance within 10 years with an AUROC of 82%; this value was significantly higher than that from models that include only level of HBV DNA and HBsAg (P < .0001). CONCLUSIONS: In a retrospective analysis of a large cohort of patients with chronic HBV infection in Taiwan, we associated levels of anti-HBc <3 log IU/mL with undetectable HBV DNA and HBsAg seroclearance occurred within 10 years; patients who also have levels of HBsAg <102 IU/mL have greater odds. Combining data on levels of HBsAg, HBV DNA, and anti-HBc is able to identify HBeAg-seronegative patients who can achieve HBsAg seroclearance with an AUROC value of 82%.
引用
- Hu HH, Liu J, Chang CL, et al. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clin Gastroenterol Hepatol. 2018. PMID: 29753083. doi:10.1016/j.cgh.2018.04.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。